Consensus $611.09M. The company said, “Inspire is increasing and narrowing its full year 2023 revenue guidance to between $608 million to $612 million, which represents growth of 49% to 50% over full year 2022 revenue of $407.9 million. This compares to the prior revenue guidance of $600 million to $610 million. The Company is maintaining its full year 2023 gross margin guidance of 83% to 85%. Inspire is also maintaining its guidance relating to the opening of new U.S. medical centers of 52 to 56 per quarter for the remaining quarter of the year, as well as its guidance of 12 to 14 new U.S. territories for the fourth quarter of 2023.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on INSP:
- Inspire Medical price target lowered to $250 from $350 at Stifel
- LivaNova price target lowered to $62 from $71 at Needham
- Inspire Medical price target lowered to $180 from $355 at BofA
- Inspire Medical price target lowered to $300 from $380 at Mizuho
- Inspire Medical initiated with a Market Perform at Leerink